| 產(chǎn)品名稱 | SaI [Sa I, Sarcoma I] |
|---|---|
| 商品貨號(hào) | B165661 |
| Organism | Mus musculus, mouse |
| Cell Type | dibenzanthracene induced |
| Product Format | frozen |
| Morphology | lymphoblast |
| Culture Properties | suspension |
| Biosafety Level | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | fibrosarcoma, malignant |
| Applications | It can be used in immunology and cancer studies. The cells may be used for transfection studies. The cell line can be used as a model for testing immunotherapy protocols. |
| Storage Conditions | liquid nitrogen vapor phase |
| Derivation | The Sarcoma I tumor originated in 1947 in a mouse that had been treated with dibenzanthracene |
| Clinical Data | The cell line can be used as a model for testing immunotherapy protocols. |
| Antigen Expression | MHC class I +; MHC class II - Ref   Baskar S, et al. Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J. Exp. Med. 181: 619-629, 1995. PubMed: 7836917H-2a |
| Genes Expressed | MHC class I +; MHC class II -,H-2a |
| Tumorigenic | Yes |
| Effects | Yes, grows as ascites in A/Jax mice but not in C57BL/6K mice Ref Baker P, et al. Mechanisms of tumor homograft rejection: The behavior of Sarcoma I ascites tumor in the A/Jax and the C57BL/6K mouse. Ann. N.Y. Acad. Sci. 101: 46-63, 1962. |
| Comments | The Sarcoma I tumor originated in 1947 in a mouse that had been treated with dibenzanthracene The tumor grows progressively in the A/Jax subline of the Strong A mouse and kills 100% of the animals. In contrast, mice of the resistant C57BL/6K strain reject the tumor in about 100% of the cases. The SaI variant (ATCC CRL-2543) grows as an ascites tumor when inoculated intraperitoneally, while the SaI/N variant grows as a solid tumor when inoculated subcutaneously The cell line can be used as a model for testing immunotherapy protocols. It can be used in immunology and cancer studies. The cells may be used for transfection studies. |
| Complete Growth Medium | The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing | Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 5 x 105 viable cells/mL. Maintain cell density between 5 x 105 and 2 x 106 viable cells/mL. Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density) |
| Cryopreservation | Complete growth medium described above supplemented with 5% (v/v) DMSO. Cell culture tested DMSO is available as ATCC Catalog No. 4-X. |
| Culture Conditions | Temperature: 37°C
Atmosphere: Air, 95%; Carbon dioxide (CO2), 5% |
| Name of Depositor | S Ostrand-Rosenberg |
| Deposited As | mouse |
| References | Baskar S, et al. Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J. Exp. Med. 181: 619-629, 1995. PubMed: 7836917 Baker P, et al. Mechanisms of tumor homograft rejection: The behavior of Sarcoma I ascites tumor in the A/Jax and the C57BL/6K mouse. Ann. N.Y. Acad. Sci. 101: 46-63, 1962. Dunham LJ, Stewart HL. A survey of transplantable and transmissible animal tumors. J. Natl. Cancer Inst. 13: 1299-1377, 1953. PubMed: 13035452 Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC. Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988. Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC. Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Washington DC: U.S. Government Printing Office; 2007. The entire text is available online. |
| 序號(hào) | 文章標(biāo)題 | 操作 |
|---|---|---|
| 1 | ATCC細(xì)胞運(yùn)輸和處理 | 查看詳情 |
| 2 | 其他海外品牌代理 | 查看詳情 |
| 3 | ATCC代理 | 查看詳情 |
| 4 | 購(gòu)買須知 | 查看詳情 |
| 5 | 訂購(gòu)流程 | 查看詳情 |
| 梅經(jīng)理 | 17280875617 | 1438578920 |
| 胡經(jīng)理 | 13345964880 | 2438244627 |
| 周經(jīng)理 | 17757487661 | 1296385441 |
| 于經(jīng)理 | 18067160830 | 2088210172 |
| 沈經(jīng)理 | 19548299266 | 2662369050 |
| 李經(jīng)理 | 13626845108 | 972239479 |
